Isbn: 9789401065580 - biological models in radiopharmaceutical development (developments in nuclear medicine, band 27) (3 Ergebnisse)

ISBN
Mit der Detailsuche verfeinern

Optimieren Sie Ihre Suche

  • Bücher (3)

  • Neu (3)

bis

Benutzerdefinierte Preisspanne (EUR)

bis

    • Sprache: Englisch

      Verlag: Springer, 2011

      9401065586 / 9789401065580

      Serie: Buch 20 von 33 - Developments in Nuclear Medicine

      • Softcover

      Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes KönigreichRia Christie Collections

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 61,04

      EUR 13,17 Versand 
      Versand von Vereinigtes Königreich nach USA

      Anzahl: Mehr als 20 verfügbar

      Zustand: New. In.

    • Sprache: Englisch

      Verlag: Springer, 2011

      9401065586 / 9789401065580

      Serie: Buch 20 von 33 - Developments in Nuclear Medicine

      • Softcover

      Anbieter: Revaluation Books, Exeter, Vereinigtes KönigreichRevaluation Books

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 78,58

      EUR 11,67 Versand 
      Versand von Vereinigtes Königreich nach USA

      Anzahl: 2 verfügbar

      Paperback. Zustand: Brand New. 272 pages. 9.45x6.30x0.65 inches. In Stock.

    • Sprache: Englisch

      Verlag: Springer, 2011

      9401065586 / 9789401065580

      Serie: Buch 20 von 33 - Developments in Nuclear Medicine

      • Softcover

      Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 78,76

      EUR 30,50 Versand 
      Versand von Deutschland nach USA

      Anzahl: 1 verfügbar

      Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Radiophannaceuticals labeled with short-lived radionuclides are utilized to unravel biochemical processes, and to diagnosis and treat diseases of the living body are-developed through extensive evaluation in ~iological models. 'fhC first attempt to compile information was a volume entitled ANIMAL MODELS IN RADIOTRACER DESIGN that was edited by William C. Eckelman and myself in 1983. The volume had a focus on the animal models that investigators were using in order to design radiotracers that displayed in vivo selectivity as measured by biodistribution and pharmacokinetic studies. A concern in the early days of nuclear medicine was species differences. Often a series of labeled compounds were evaluated in a several different animal models in order to gain confidence that the selected radiotracer would behave appropriately in humans. During the past 12 years there have been remarkable advances in molecular genetics, molecular biology, synthetic radiopharmaceutical chemistry, molecular modeling and visualization, and emission tomography. Biological models can now be selected that are better defined in terms of molecular aspects of the disease process. The development of high resolution PET and SPET for clinical applications facilitates the development of new radiopharmaceuticals by the use of models to quantitatively evaluate drug effects, and progression of disease, and hence to arrive at better diagnosis and treatments for animals and humans. With these advances there is an effective use of biological models, and the refinement of alternatives for the development of new radiophannaceuticals.